Literature DB >> 1694199

Generation and characterization of hamster-mouse hybridomas secreting monoclonal antibodies with specificity for lipopolysaccharide receptor.

S W Bright1, T Y Chen, L M Flebbe, M G Lei, D C Morrison.   

Abstract

Experiments are described for the partial purification of the 80-kDa LPS binding protein expressed on macrophages and lymphocytes. This partially purified Ag was used to immunize adult Armenian hamsters and splenocytes from immunized animals were fused with murine myeloma cell lines. Hybridoma cell culture supernatants containing mAb were screened by ELISA for positive binding to the immunizing Ag, murine splenocytes and the murine 70Z/3 pre B cell and for an absence of binding to sheep E. Positive clones were further screened for reciprocal competitive binding with LPS on spleen cells and ability to modulate B lymphocyte mitogenic activity. Two hybridoma cell lines secreting IgM monoclonals, termed mAb3D7 and mAb5D3, were identified that satisfied all of the selection criteria. These hybridoma cell lines were subcloned and expanded. Binding of one (mAb3D7) was abrogated by treatment of Ag with mild periodate; binding of the second (mAb5D3) was destroyed by digestion of Ag with proteinase K. Binding specificity for mAb5D3 has been confirmed by ELISA using highly purified 80-kDa protein. These mAb have been of value in establishing that the 80-kDa LPS binding protein previously identified may serve as a specific functional receptor for LPS.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1694199

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  9 in total

1.  Identification and characterization of lipopolysaccharide-binding proteins on human peripheral blood cell populations.

Authors:  J L Halling; D R Hamill; M G Lei; D C Morrison
Journal:  Infect Immun       Date:  1992-03       Impact factor: 3.441

2.  Lipopolysaccharide-induced NF-kappa B activation in mouse 70Z/3 pre-B lymphocytes is inhibited by mevinolin and 5'-methylthioadenosine: roles of protein isoprenylation and carboxyl methylation reactions.

Authors:  R E Law; J B Stimmel; M A Damore; C Carter; S Clarke; R Wall
Journal:  Mol Cell Biol       Date:  1992-01       Impact factor: 4.272

3.  Lipopolysaccharide binding proteins on polymorphonuclear leukocytes: comparison of adult and neonatal cells.

Authors:  G Qing; S Howlett; R Bortolussi
Journal:  Infect Immun       Date:  1996-11       Impact factor: 3.441

4.  Bacterial lipopolysaccharide stimulates protein tyrosine phosphorylation in macrophages.

Authors:  S L Weinstein; M R Gold; A L DeFranco
Journal:  Proc Natl Acad Sci U S A       Date:  1991-05-15       Impact factor: 11.205

5.  Evidence that lipopolysaccharide and pertussis toxin bind to different domains on the same p73 receptor on murine splenocytes.

Authors:  M G Lei; D C Morrison
Journal:  Infect Immun       Date:  1993-04       Impact factor: 3.441

6.  The 70-kilodalton pertussis toxin-binding protein in Jurkat cells.

Authors:  G D Armstrong; C G Clark; L D Heerze
Journal:  Infect Immun       Date:  1994-06       Impact factor: 3.441

7.  Involvement of tyrosine kinase in the induction of cyclo-oxygenase and nitric oxide synthase by endotoxin in cultured cells.

Authors:  P Akarasereenont; J A Mitchell; I Appleton; C Thiemermann; J R Vane
Journal:  Br J Pharmacol       Date:  1994-12       Impact factor: 8.739

8.  CD14 is not involved in Rhodobacter sphaeroides diphosphoryl lipid A inhibition of tumor necrosis factor alpha and nitric oxide induction by taxol in murine macrophages.

Authors:  F Kirikae; T Kirikae; N Qureshi; K Takayama; D C Morrison; M Nakano
Journal:  Infect Immun       Date:  1995-02       Impact factor: 3.441

9.  The mucin epiglycanin on TA3/Ha carcinoma cells prevents alpha 6 beta 4-mediated adhesion to laminin and kalinin and E-cadherin-mediated cell-cell interaction.

Authors:  H Kemperman; Y Wijnands; J Wesseling; C M Niessen; A Sonnenberg; E Roos
Journal:  J Cell Biol       Date:  1994-12       Impact factor: 10.539

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.